labetalol has been researched along with Obesity in 5 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetic data for the three drugs were qualitatively similar." | 2.68 | Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. ( Carrupt, PA; Cheymol, G; Levron, JC; Poirier, JM; Snoeck, E; Testa, B; Weissenburger, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsofliou, F | 1 |
| Pitsiladis, YP | 1 |
| Lara, J | 1 |
| Hadjicharalambous, M | 1 |
| Macdonald, IA | 1 |
| Wallace, MA | 1 |
| Lean, MEJ | 1 |
| Fynn, J | 1 |
| Venyo, AK | 1 |
| Cheymol, G | 1 |
| Poirier, JM | 1 |
| Carrupt, PA | 1 |
| Testa, B | 1 |
| Weissenburger, J | 1 |
| Levron, JC | 1 |
| Snoeck, E | 1 |
| Abate, MA | 1 |
| Neely, JL | 1 |
| Layne, RD | 1 |
| D'Alessandri, R | 1 |
| Messerli, FH | 1 |
1 review available for labetalol and Obesity
| Article | Year |
|---|---|
Hemodynamic and cardiac adaptation in essential hypertension. Consequences for therapy.
Topics: Adaptation, Physiological; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aging; Black People | 1985 |
3 trials available for labetalol and Obesity
| Article | Year |
|---|---|
The effects of moderate alterations in adrenergic activity on acute appetite regulation in obese women: A randomised crossover trial.
Topics: Adrenergic Agents; Adrenergic beta-Antagonists; Appetite; Appetite Regulation; Blood Glucose; Cross- | 2020 |
Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Adult; Area Under Curve; Benzopyrans; Binding Sites; Bi | 1997 |
Interaction of indomethacin and sulindac with labetalol.
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Body Weight; Chlorides; Drug Interactions; Humans | 1991 |
1 other study available for labetalol and Obesity
| Article | Year |
|---|---|
Renal cell carcinoma presenting as hypertension in pregnancy.
Topics: Adult; Antihypertensive Agents; Body Mass Index; Carcinoma, Renal Cell; Diagnosis, Differential; Fem | 2004 |